Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders.
Oculogenex has raised $1.0M in total funding. The most recent round was Grant. The last funding was announced in May 2022.
Oculogenex's investors include National Science Foundation, MassChallenge.
Oculogenex is headquartered in La Habra, United States.
Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders.
Oculogenex is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oculogenex — Funding & Investors." VCBacked, May 2, 2022, https://www.vcbacked.co/company/oculogenex. Accessed October 31, 2026.
VCBacked. (2022). Oculogenex — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/oculogenex
{{cite web |title=Oculogenex — Funding & Investors |url=https://www.vcbacked.co/company/oculogenex |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated